Trevi Therapeutics (TRVI) CSO awarded stock options on 85,000 shares

Rhea-AI Filing Summary

Trevi Therapeutics, Inc. reported that its Chief Scientific Officer, Thomas Sciascia, received a grant of stock options covering 85,000 shares of common stock. The options were awarded at an exercise price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase. According to the filing, these 85,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, and the vesting is conditioned on his continued service with the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SCIASCIA THOMAS

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.56	02/19/2026		A		85,000		(1)	02/18/2036	Common Stock	85,000	$0	85,000	D

Explanation of Responses:

1. This option was granted on February 19, 2026. The 85,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

	/s/ Christopher Galletta, attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Trevi Therapeutics (TRVI) report for Thomas Sciascia?

Trevi Therapeutics reported that Chief Scientific Officer Thomas Sciascia received a grant of stock options for 85,000 shares of common stock. The options represent a compensatory award rather than an open-market buy or sell transaction.

How many Trevi Therapeutics (TRVI) shares are covered by the new option grant?

The new option grant to Chief Scientific Officer Thomas Sciascia covers 85,000 shares of Trevi Therapeutics common stock. These shares are subject to a multi-year vesting schedule tied to his continued service with the company.

What is the vesting schedule for the 85,000 TRVI stock options granted to Thomas Sciascia?

The 85,000 Trevi Therapeutics stock options granted to Thomas Sciascia vest in equal monthly installments through February 19, 2030. Vesting depends on his continued service with the issuer over this period.

Was the Trevi Therapeutics (TRVI) option grant to Thomas Sciascia an open-market purchase?

No, the transaction is described as a grant or award of stock options, not an open-market purchase. The options were issued at an exercise price of $0.00 per share as part of his compensation.

Does Thomas Sciascia directly own the granted Trevi Therapeutics (TRVI) options?

Yes, the filing classifies ownership of the 85,000 stock options as direct. After this compensatory grant, he is shown as directly holding 85,000 derivative securities tied to Trevi Therapeutics common stock.